Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling.
暂无分享,去创建一个
S. Majumdar | M. Bouxsein | L. Palermo | D. Black | C. Rosen | D. Newitt | J. McGowan | Eyal Rosen
[1] R. Lindsay,et al. Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis , 2007, Annals of Internal Medicine.
[2] K. Michaud,et al. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. , 2006, Archives of internal medicine.
[3] John P. Bilezikian,et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis , 2006 .
[4] E. Schwartz,et al. Combination Teriparatide and Raloxifene Therapy for Postmenopausal Osteoporosis: Results From a 6‐Month Double‐Blind Placebo‐Controlled Trial , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[5] D. Newitt,et al. Effects of Salmon Calcitonin on Trabecular Microarchitecture as Determined by Magnetic Resonance Imaging: Results From the QUEST Study , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] R. Lindsay,et al. Daily and cyclic parathyroid hormone in women receiving alendronate. , 2005, The New England journal of medicine.
[7] G. Dalsky,et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. , 2005, Archives of internal medicine.
[8] M. Hochberg,et al. Treatment With Once‐Weekly Alendronate 70 mg Compared With Once‐Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double‐Blind Study , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[9] J. Rodriguez-Portales,et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. , 2004, The New England journal of medicine.
[10] Mary L Bouxsein,et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. , 2003, The New England journal of medicine.
[11] A. Díez-Pérez,et al. The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With Osteoporosis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[12] S. Majumdar,et al. Processing and Analysis of In Vivo High-Resolution MR Images of Trabecular Bone for Longitudinal Studies: Reproducibility of Structural Measures and Micro-Finite Element Analysis Derived Mechanical Properties , 2002, Osteoporosis International.
[13] J. Reginster,et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.
[14] H K Genant,et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.
[15] C C Glüer,et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.
[16] M. Fukunaga,et al. Effect of an Intermittent Weekly Dose of Human Parathyroid Hormone (1-34) on Osteoporosis: A Randomized Double-Masked Prospective Study Using Three Dose Levels , 1999, Osteoporosis International.
[17] P. Rüegsegger,et al. Calibration of trabecular bone structure measurements of in vivo three-dimensional peripheral quantitative computed tomography with 28-microm-resolution microcomputed tomography. , 1999, Bone.
[18] H K Genant,et al. Assessment of vertebral bone mineral density using volumetric quantitative CT. , 1999, Journal of computer assisted tomography.